Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:March 7, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:March 7, 2024Recruiting
Condition(s):Breast CancerLast Updated:April 18, 2023Recruiting
Condition(s):Breast CancerLast Updated:November 30, 2020Recruiting
Condition(s):Hormone Receptor-positive Advanced Breast CancerLast Updated:April 14, 2023Not yet recruiting
Condition(s):Endometroid Endometrial CancerLast Updated:February 22, 2024Recruiting
Condition(s):Advanced Breast CancerLast Updated:September 15, 2022Not yet recruiting
Condition(s):Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA MutationLast Updated:September 21, 2023Recruiting
Condition(s):Hormone Receptor-positive Advanced Breast CancerLast Updated:April 10, 2023Not yet recruiting
Condition(s):HR Positive/HER-2 Negative Breast CancerLast Updated:December 15, 2023Not yet recruiting
Condition(s):Advanced Solid Tumor; Breast CancerLast Updated:November 22, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.